EP Patent

EP1782795A1 — Ophthalmic gel made up of triamcinolone acetonide and a polyacrylic polymer

Assigned to Sooft Italia SpA · Expires 2007-05-09 · 19y expired

What this patent protects

For the preparation of ophthalmic gels containing triamcinolone acetonide as active principle, use is envisaged of gelifying agents, such as homopolymers of acrylic acid cross-linked with an alkyl sucrose or with an alkyl pentaerythritol (carbopol - carbomer). The triamcino…

USPTO Abstract

For the preparation of ophthalmic gels containing triamcinolone acetonide as active principle, use is envisaged of gelifying agents, such as homopolymers of acrylic acid cross-linked with an alkyl sucrose or with an alkyl pentaerythritol (carbopol - carbomer). The triamcinolone acetonide gel obtained can be used as contrast agent of the vitreous body in ophthalmic surgery, as medicament for treatment of ocular pathologies with an allergic and/or inflammatory base, and for treatment of diabetic macular oedema.

Drugs covered by this patent

Patent Metadata

Patent number
EP1782795A1
Jurisdiction
EP
Classification
—
Expires
2007-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Sooft Italia SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.